CLDN18.2靶向ADC 3期研究达到双主要终点；双靶点ADC 3期结果积极……

同花顺07:35

CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物（HK1801）(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tavatecan治疗晚期胃癌的国际性3期G-HOPE-001研究结果。研究同时达到无进展生存期(PFS)和总生存期(OS)两项主要终点，显著延长既往接受过多线...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2677276908?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-10-24 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677276908","market":"fut","top_or_hot":-1,"title":"CLDN18.2靶向ADC 3期研究达到双主要终点；双靶点ADC 3期结果积极……","media":"同花顺","content":"<div>\n<p>CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物（HK1801）(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tavatecan治疗晚期胃癌的国际性3期G-HOPE-001研究结果。研究同时达到无进展生存期(PFS)和总生存期(OS)两项主要终点，显著延长既往接受过多线...</p>\n\n<a href=\"http://news.10jqka.com.cn/20261024/c681047440.shtml\">网页链接</a>\n\n</div>\n","source":"tonghuashun_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLDN18.2靶向ADC 3期研究达到双主要终点；双靶点ADC 3期结果积极……</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLDN18.2靶向ADC 3期研究达到双主要终点；双靶点ADC 3期结果积极……\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-24 07:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://news.10jqka.com.cn/20261024/c681047440.shtml><strong>同花顺</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物（HK1801）(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tavatecan治疗晚期胃癌的国际性3期G-HOPE-001研究结果。研究同时达到无进展生存期(PFS)和总生存期(OS)两项主要终点，显著延长既往接受过多线...</p>\n\n<a href=\"http://news.10jqka.com.cn/20261024/c681047440.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0096364046.USD","symbol_name":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","start_time":0,"source_url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","article_id":"2677276908","we_media_id":null,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677276908","pubTimestamp":1792798500,"columns":[],"sourceInfo":{"source_id":"tonghuashun_highlight","name":"同花顺"},"weMediaInfo":null,"summary":" CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tava ...","collect":0,"end_time":0,"defaultTopTitle":"10jqka.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","ITT":"ITT Inc.","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4559":"巴菲特持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","PFS":"Provident Financial Services Inc","ADC":"艾格里房产","BMY":"施贵宝","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","GMAB":"Genmab A/S","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0237698245.USD":"富达环球地产基金A","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","FFBC":"第一金融银行股份","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4211":"区域性银行","NETL":"NETLease Corporate Real Estate ETF","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4195":"互助储蓄与抵押信贷金融服务","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","ORR":"Militia Long/Short Equity ETF","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4231":"零售房地产信托","BK4585":"ETF&股票定投概念","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IHE":"iShares U.S. Pharmaceuticals ETF","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC"},"translate_title":"The Phase 3 study of CLDN18.2 targeting ADC reached two primary endpoints; Dual-target ADC Phase 3 results are positive...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FFBC":1,"IHE":0.6,"ORR":1,"PFS":1,"NETL":0.6,"ADC":1,"FTXH":0.6,"ITT":1,"GMAB":1,"BMY":1},"content_text":"CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物（HK1801）(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tavatecan治疗晚期胃癌的国际性3期G-HOPE-001研究结果。研究同时达到无进展生存期(PFS)和总生存期(OS)两项主要终点，显著延长既往接受过多线治疗的CLDN18.2阳性晚期胃癌患者的生存期。 G-HOPE-001是一项国际性多中心、随机、开放标签3期研究，共纳入464例既往接受过2至4线系统治疗的CLDN18.2阳性、不可切除局部晚期或转移性胃癌或胃食管交界部腺癌患者。受试者按1：1比例接受每3周一次、剂量为6mg/kg的arcotatug tavatecan，或研究者选择的伊立替康、紫杉醇或曲氟尿苷/替匹嘧啶治疗。最新分析显示，arcotatug tavatecan组的中位总生存期达到10.2个月，对照组为6.9个月，死亡风险降低43%(HR=0.57，95%CI：0.45～0.73，P<0.0001)。经独立影像学评估，两组中位PFS分别为7.1个月和3.1个月(HR=0.45，95%CI：0.35～0.58)，经确认的客观缓解率分别为37.4%和7.7%。 Arcotatug tavatecan是一款靶向紧密连接蛋白CLDN18.2的ADC，通过抗体将拓扑异构酶1抑制剂exatecan递送至表达CLDN18.2的肿瘤细胞。该药还采用Fc效应功能沉默设计，旨在降低抗体Fc段介导的非肿瘤组织毒性风险。CLDN18.2在正常胃黏膜组织中主要位于细胞间紧密连接区域，在部分胃癌等实体瘤中则异常暴露于肿瘤细胞表面，因此成为近年来胃癌靶向药物开发的重要靶点。 EGFR/HER3双靶点ADC3期结果积极，降低59%乳腺癌疾病进展或死亡风险百时美施贵宝（BMY）(Bristol Myers Squibb)与SystImmune宣布，靶向表皮生长因子受体(EGFR)和人表皮生长因子受体3(HER3)的双特异性ADC izalontamab brengitecan(iza-bren)治疗激素受体阳性(HR+)、人表皮生长因子受体2(HER2)阴性晚期乳腺癌的3期PANKU-Breast01研究取得积极结果。研究达到PFS主要终点，使患者疾病进展或死亡风险降低59%。 PANKU-Breast01是一项随机3期研究，共纳入383例既往至少接受过一线化疗后疾病进展的不可切除局部晚期、复发性或转移性HR+/HER2阴性乳腺癌患者。其中190例患者接受iza-bren治疗，193例接受化疗。主要终点为盲态独立中心审查(BICR)评估的PFS。 PFS中位随访时间为15.2个月时，iza-bren组的中位PFS达到8.2个月，对照组为4.0个月，疾病进展或死亡风险降低59%(HR=0.41，95%CI：0.33～0.53，P<0.0001)。此外，两组经确认的客观缓解率(cORR)分别为40.5%和20.2%，中位缓解持续时间分别为6.9个月和4.2个月。 Iza-bren是一款在研的潜在“First（FFBC）-in-class”双特异性ADC，可同时靶向EGFR和HER3。这两个受体均参与肿瘤细胞增殖和存活相关信号传导。通过双靶点结合，iza-bren能够识别表达EGFR或HER3的肿瘤细胞，并在内化后释放拓扑异构酶1抑制剂载荷，诱导肿瘤细胞死亡。该药还被设计为能够阻断EGFR和HER3相关信号，进一步抑制肿瘤细胞增殖。FRα靶向ADC3期结果积极，卵巢癌患者疾病进展或死亡风险降低71% Genmab（GMAB）宣布，在研抗体偶联药物rinatabart sesutecan(Rina-S)治疗铂耐药卵巢癌的全球3期RAINFOL-02研究获得积极顶线结果。研究达到PFS主要终点及OS关键次要终点，显著降低患者的疾病进展或死亡风险。值得关注的是，在不同叶酸受体α(FRα)表达水平的患者中均观察到相关获益。 RAINFOL-02是一项全球性、多中心、随机、开放标签3期研究，共有584例铂耐药卵巢癌患者接受随机分组，不限制FRα表达水平。受试者按1：1比例接受每3周一次、剂量为120mg/m 的Rina-S，或研究者选择的紫杉醇、拓扑替康、聚乙二醇化脂质体多柔比星或吉西他滨治疗。主要终点为研究者评估的PFS，关键次要终点包括OS和客观缓解率(ORR)。结果显示，在全部随机患者组成的意向治疗(ITT)人群中，与对照组相比，Rina-S使疾病进展或死亡风险降低71%(HR=0.29，95%CI：0.23～0.37，P<0.0001)，死亡风险降低57%(HR=0.43，95%CI：0.31～0.59，P<0.0001)。在预设的492例主要分析人群中，该药使疾病进展或死亡风险降低67%(HR=0.33，95%CI：0.26～0.42)，死亡风险降低56%(HR=0.44，95%CI：0.31～0.63)，均达到统计学显著性。 Rina-S是一款靶向FRα的ADC，由靶向抗体与拓扑异构酶1(TOPO1)抑制剂载荷组成，通过抗体识别肿瘤细胞表面的FRα，将细胞毒性药物递送至肿瘤细胞内发挥作用。[1]Takeda Announces Arcotatug Tavatecan(TAK-921)Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase3Advanced Gastric Cancer Study.Retrieved October23,2026,from https://www.takeda.com/newsroom/newsreleases/2026/arcotatug-tavatecan-phase-3-study/[2]Izalontamab Brengitecan(Iza-Bren)Reduced Risk of Disease Progression or Death by59%versus Chemotherapy in Patients with Advanced HR+/HER2-Breast Cancer in Phase3PANKU-Breast01Study.Retrieved October23,2026,from https://news.bms.com/news/corporate-financial/2026/Izalontamab-Brengitecan-Iza-Bren-Reduced-Risk-of-Disease-Progression-or-Death-by-59-versus-Chemotherapy-in-Patients-with-Advanced-HRHER2--Breast-Cancer-in-Phase-3-PANKU-Breast01-Study/default.aspx [3]Genmab（GMAB） Announces Rinatabart Sesutecan(Rina-S )Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer.Retrieved October23,2026,from https://www.businesswire.com/news/home/20261023662606/en/Genmab（GMAB）-Announces-Rinatabart-Sesutecan-Rina-S-Demonstrates-Statistically-Significant-Improvement-in-Progression-Free-Survival-and-Overall-Survival-in-Patients-with-Platinum-Resistant-Ovarian-Cancer","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677276908","isCrawlerRequest":true}